This publication is provided for historical reference only and the information may be out of date.
- ACE
Angiotensin-converting enzyme
- ACEI(s)
Angiotensin-converting enzyme inhibitor(s)
- AHRQ
Agency for Healthcare Research and Quality
- ARB(s)
Angiotensin II receptor blocker(s)/antagonist(s)
- AT 1
Angiotensin specific receptor
- CER
Comparative Effectiveness Review
- DBP
Diastolic blood pressure
- EF
Ejection fraction
- EPC
Evidence-based Practice Centers
- ESRD
End-stage renal disease
- GFR
Glomerular filtration rate
- HgbA1c
Glycated hemoglobin
- HCTZ
Hydrochlorothiazide
- HDL
High-density lipoprotein
- LDL
Low-density lipoprotein
- LV
Left ventricular
- LVEF
Left ventricular ejection fraction
- LVH
Left ventricular hypertrophy
- LVMI
Left ventricular mass index
- MeSH
Medical Subject Headings
- MI
Myocardial infarction
- RCT
Randomized controlled trial
- SBP
Systolic blood pressure
- SD
Standard deviation
- SF-36
Medical Outcomes Study 36-Item Short Form Health Survey
- SRC
Scientific Resource Center
- TC
Total cholesterol
- TG
Triglyceride
- UAE
Urinary albumin excretion
- USPSTF
U.S. Preventive Services Task Force
Publication Details
Copyright
Publisher
Agency for Healthcare Research and Quality (US), Rockville (MD)
NLM Citation
Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Nov. (Comparative Effectiveness Reviews, No. 10.) Abbreviations.